Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance. (2019)
Attributed to:
A GMP cell therapy facility to test cell based therapies
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/thoraxjnl-2017-211439
PubMed Identifier: 29622695
Publication URI: http://europepmc.org/abstract/MED/29622695
Type: Journal Article/Review
Volume: 74
Parent Publication: Thorax
Issue: 2
ISSN: 0040-6376